معرفی
Firas Aljabery serves as an Adjunct Assistant Professor at Linköping University, holding dual appointments in the Department of Surgery, Orthopaedics and Oncology (KOO) and the Department of Biomedical and Clinical Sciences (BKV). His academic profile centers on clinical urology and oncology research with emphasis on bladder cancer epidemiology and translational studies leveraging Sweden's national healthcare registries.
Dr. Aljabery's research program addresses critical gaps in bladder cancer management through five key domains: gender-based survival disparities following radical cystectomy, multidisciplinary team referral optimization using the MeDiC score, secondary cancer risk assessment after non-muscle-invasive disease, national clinical guideline development for advanced urothelial carcinoma, and urinary biomarker validation for malignancy stratification. His work consistently utilizes population-based cohort methodologies with nationwide Swedish datasets to generate evidence for clinical decision-making.
Analysis of his 2025 publications reveals a cohesive research trajectory focused on improving bladder cancer outcomes through system-level interventions and molecular diagnostics. These studies demonstrate strong alignment with national guideline committees and cancer registry initiatives, emphasizing real-world applicability of findings for urologic oncology practice. The collaborative nature of his work spans multiple Swedish institutions and clinical specialties.
No scientific awards or honors were documented in the source materials.
While specific grant funding and student supervision details were not provided, his involvement in nationwide population studies and guideline committees indicates participation in significant collaborative research initiatives. The publication patterns suggest engagement with both clinical urology teams and translational research groups.
Dr. Aljabery's work positions him within Sweden's national urologic cancer research infrastructure, particularly through contributions to the Swedish National Guidelines group for urothelial carcinoma. His dual departmental affiliations reflect integration between surgical oncology (KOO) and translational biomedical research (BKV) environments at Linköping University.
